Logo

AbbVie Presents Results of AGN-190584 in P-III GEMINI 1 Study for Presbyopia at 2021 ASCRS

Share this

AbbVie Presents Results of AGN-190584 in P-III GEMINI 1 Study for Presbyopia at 2021 ASCRS

Shots:

  • The P-III GEMINI 1 study involves assessing AGN-190584 (pilocarpine 1.25%- qd) ophthalmic solution in 323 patients in a ratio (1:1) with presbyopia for 30days.
  • The study demonstrated that AGN-190584 met both its 1EPs & 2EPs with patients achieving near & intermediate vision gains. In addition- AGN-190584 showed no loss of distance vision- rapid onset of action and sustained vision gains of up to 6hrs.
  • PRO data showed improvement in ability and satisfaction in near vision reading as well as a reduction in the use of presbyopia coping mechanisms during the last 7days of the trial. If approved- AGN-190584 is expected to be the first eye drop for presbyopia

­ Ref: PRNewswire  | Image:abbvie

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions